2
21St.Bio
Helps customers optimising and developing the appropriate expression platform for large-scale production of their particular molecule by testing the molecule using various expression platforms, such…
About 21St.Bio
21st Bio is a startup operating in the industrial biotech sector, specializing in bridging the gap between innovation and viable business. The company's primary function is to assist other businesses in the successful delivery of their biotech products. They achieve this by leveraging their extensive experience, a proven technology platform, and unique manufacturing capabilities.
Read full description
Their clients are typically other businesses in the biotech industry who have developed innovative products but need assistance in bringing these products to market. 21st Bio's role is to help these businesses optimize their production processes to ensure high-quality, cost-effective delivery of their products.
The company's business model revolves around providing a range of services to their clients. These services include the development and optimization of strains for high titer and product stability, lab-scale fermentation development for superior productivity, and the development of recovery and purification processes for a high-quality product. They also assist with the scale-up of fermentation and downstream processes.
21st Bio generates revenue by charging for these services. The company's competitive advantage lies in its ability to provide these services at a competitive cost, thanks to its world-class manufacturing platform.
In summary, 21st Bio is a key player in the industrial biotech sector, providing essential services to businesses that need help in delivering their innovative products to market in a cost-effective and efficient manner.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Gladsaxe Municipality, Denmark
- Employees
- 66
- Open positions
- 2
- Dealroom signal
- 78.4/100
- Sub-industry
- AgriTech
- Sector
- Food, Biotechnology, Biomaterials, Synthetic Biology, Sustainable Development Goals, Fermentation, Biotechnology in Food, Climate Tech, Nordic Rising Star 2022, Top 50 Nordic Rising Star 2022 Denmark, Enablers of Synthetic Biology
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Apr 2024
- Capital deployed
- $20M
- Preferred round
- SERIES A
Latest news
Press, funding announcements and product moves mentioning 21St.Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Dec 2021 | $95M | $378M | Novo Holdings · Novo Seeds | ↗ |
Growth signals
Latest recorded traffic for 21St.Bio is 4.9K monthly website visits, up 96% over the last three months. 21St.Bio's team grew 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Novo Holdings
Novo Seeds
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about 21St.Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See 21St.Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.